Praxis Reports Q1 Net Loss of $92.6M, EPS $(3.20) Amidst Clinical Progress
Summary
Praxis Precision Medicines reported a net loss of $92.6 million and an EPS loss of $3.20 for the first quarter of 2026. This represents a wider net loss compared to the prior year, although diluted EPS slightly improved from $(3.29) to $(3.20). This earnings report follows the 10-Q filing earlier today, which highlighted a significant public offering that boosted cash reserves to $1.4 billion. While the company continues to incur losses as it advances its pipeline, the article notes positive clinical milestones, including Phase 3 results for ulixacaltamide and accepted NDAs, alongside a strong cash runway expected to support operations into 2028. Traders will weigh the operational losses against the company's substantial liquidity and clinical advancements.
At the time of this announcement, PRAX was trading at $339.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.4B. The 52-week trading range was $34.89 to $356.00. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.